November 18, 2025 — Leads & Copy — Arcellx, Inc. (NASDAQ: ACLX) will host an Investor Relations event on Saturday, December 6, 2025, at 8:00 p.m. ET, featuring a panel of clinician experts to discuss the latest data from the Phase 2 pivotal iMMagine-1 study in relapsed or refractory multiple myeloma patients.
The live webcast of the event will be accessible on Arcellx’s website in the Investors section. An archived replay will be available for 30 days following the event.
Arcellx, Inc., a clinical-stage biotechnology company, is focused on engineering innovative immunotherapies for cancer and other incurable diseases. The company’s mission is to advance humanity by developing safer, more effective, and broadly accessible cell therapies.
Arcellx believes cell therapies are forward pillars of medicine. Follow Arcellx on X @arcellx and LinkedIn.
This press release contains forward-looking statements based on current expectations that involve assumptions, risks, and uncertainties. These statements are neither promises nor guarantees, and actual results may differ materially. Reference is made to the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, filed with the SEC on November 5, 2025, for a discussion of potential risks.
Arcellx assumes no obligation to update or revise these statements.
Source: Arcellx, Inc.
